Table 1 Comparison of demographic data and clinical characteristics between the two groups. Yrs: years; BMI: body mass index; HTN: hypertension; DM: diabetes mellitus; DLD: dyslipidemia disease; ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blockers; CCB: calcium channel blocker; S.D: standard deviation. (#): unpaired t test; (##): paired t test; ($): Chi-Square test; (@): Mann Whitney U test. P value 1 is for comparison variables between the two groups; P value 2 is for comparison variables in one group; *P value < 0.05 is considered significant.
Parameter | Control group: N (36) | Curcumin group: N (36) | P value 1 |
|---|---|---|---|
Age (yrs): Mean ± S.D | 60.9 ± 6.6 | 59.8 ± 5.3 | 0.433# |
Height (cm): Mean ± S.D | 155.8 ± 7.6 | 158.9 ± 6.5 | 0.073# |
Weight (Kg): Mean ± S.D | |||
Baseline | 87.3 ± 14.3 | 88.4 ± 13.4 | 0.741# |
End of study | 87.4 ± 15.4 | 87.9 ± 13.3 | 0.890# |
P value 2 | 0.800## | 0.155## | |
BMI (kg/m2): Mean ± S.D | |||
Baseline | 36.1 ± 6.0 | 35.1 ± 5.2 | 0.462# |
End of study | 36.1.3 ± 6.5 | 34.9 ± 5.2 | 0.389# |
P value 2 | 0.798## | 0.223## | |
Gender: N (%) | |||
Male | 3(8.3%) | 3(8.3%) | 1.00$ |
Female | 33(91.7) | 33(91.7) | |
Smokers: N (%) | 3 (8.3%) | 6(16.7%) | 0.478$ |
Exercise: N (%) | 13(36.1%) | 9 (25.0%) | 0.306$ |
Diet: N (%) | |||
Healthy | 9(25.0%) | 17(47.2%) | 0.050$ |
Unhealthy | 27(75.0%) | 19(52.8%) | |
Medical history: N (%) | |||
None | 35(97.2%) | 31(86.1% | |
With diseases | 1(2.8%) | 5(13.9%) | |
Thyroid disease | 1(2.8%) | 0(0.0%) | 0.199$ |
Surgical operations | 0(0.0%) | 2(5.6%) | |
Other diseases | 0(0.0%) | 3(8.3%) | |
Duration of HTN (yrs): Median (Range) | 10 (1–29) | 10 (1–40) | 0.475@ |
Duration of DM (yrs): Median (Range) | 15(2–35) | 10(3–30) | 0.163@ |
Duration of DLD (yrs): Median (Range) | 4.5(1–15) | 2(1–10) | 0.092@ |
Medications: N (%) | |||
Antihypertensives | |||
Beta blockers | 16 (44.4%) | 11(30.6%) | 0.224$ |
Diuretics | 2(5.6%) | 2(5.6%) | 1.000$ |
ACE inhibitors | 19(52.8%) | 16(44.4%) | 0.479$ |
ARB&CCB | 7(19.4%) | 13(36.1%) | 0.114$ |
Antidiabetics | |||
Insulin | 22(61.1%) | 17(47.2%) | 0.237$ |
Insulin & Metformin | 19(52.8%) | 12(33.3%) | 0.096$ |
Dual oral therapy | 12(33.3%) | 17(47.2%) | 0.230$ |
Insulin & Dual oral therapy | 1(1.4.%) | 2(5.6%) | 0.555$ |
Antihyperlipidemics | |||
Statins | 33(91.7%) | 32(88.9%) | 1.000$ |
Ezetimibe & simvastatin | 3(8.3%) | 4(11.1%) | 1.000$ |
